Perforin-IN-2, a benzosulfonamide perforin inhibitor, mitigates transplant rejection in allogeneic bone marrow or stem cell transplantation. It binds to plasma proteins with a binding rate of 99.8%. In vivo, a concentration higher than 900 μM is required for optimal perforin inhibition. Perforin-IN-2 effectively inhibits the lytic activity of recombinant perforin on Jurkat T leukemia cells, with an IC50 of 6.65 μM, and also prevents the death of K562 leukemia target cells [1].
Potent Smo antagonist (IC50 = 5 nM). Attenuates the leukemia-initiation potential of AML cells in a serial transplantation mouse model. Also eliminates self-propagation capacity of AML cells. Munchhof et al (2011) Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med.Chem.Lett. 3 106 PMID:24900436 |Fukushima et al (2016) Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 107 1422 PMID:27461445 |Giordani et al (2016) The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells. Oncotarget 7 55313 PMID:27486815